This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
Unifiram
DM-232 | Italian-academic racetam-class research compound (sister to sunifiram)
Aliases (3)
Overview
What is Unifiram?
Unifiram (DM-232) is the slightly less-famous sibling of sunifiram (DM-235) — both came out of the same Italian academic pharmacology program at the Università di Firenze in the early 2000s. Both are described as 'racetam-class' cognitive enhancers in community usage despite lacking the pyrrolidone ring of true racetams (the label is loose). Investigational research compound; not FDA-approved; not approved as a drug anywhere; sold as research chemical only. WADA: unscheduled.
Key Benefits
Reverses scopolamine-induced amnesia in mice at low doses (Galeotti 2007). Hypothesized AMPA receptor modulation with cholinergic enhancement, by analogy with sunifiram. Anecdotal community use describes verbal fluency and working memory effects at 5-15 mg sublingual — but with zero human trials, no published PK, and an unknown half-life in humans, the entire human-effect profile is forum-derived. The 'roughly 1000x more potent than piracetam' community claim is a rodent passive-avoidance dose ratio, not validated in humans.
Mechanism of Action
By analogy with sunifiram: indirect AMPA receptor potentiation enhancing glutamatergic transmission and long-term potentiation, with cholinergic system enhancement underlying the anti-amnesic effect in scopolamine-induced amnesia models. NMDA glycine-site involvement plausible by analogy but not directly published for unifiram. Direct unifiram-specific mechanism data is thinner than the sunifiram literature.
Peptide Interactions
Forum convention by analogy with sunifiram — AMPA potentiation increases acetylcholine demand, so a choline floor reduces headache risk.
Theoretically additive AMPA potentiation; risk = compounded seizure-threshold concern.
Additive AMPA modulation = additive seizure liability and redundant mechanism.
Independent seizure-threshold liability.
Lowers seizure threshold.
Quality Indicators
COA from third-party lab
Reputable RC vendors should provide a Certificate of Analysis (HPLC purity, mass spec ID). Verify lot number matches COA. Prefer >98% purity.
White to off-white crystalline powder
Unifiram should appear as a fine white or off-white powder. No discoloration, no clumping from moisture exposure.
No COA available
Many unifiram vendors do not provide COAs. Without independent purity verification, potency and identity are unknown. Smaller vendor footprint than sunifiram.
Significantly lower price than market range
Unifiram below $20/gram is suspicious — likely under-dosed, mis-identified, or contaminated.
Color, odor, or texture irregularity
Yellow tint, ammonia/solvent smell, or sticky/wet texture all indicate degraded or contaminated material. Discard.
Vendor with no track record or anonymous sourcing
Research chem space has high variability; established vendors with consistent COA history are the only marginally-acceptable path. Anonymous one-off vendors are not.
What to Expect
- Week 1Tolerability and dose-response.
- Week 2-4Early effect window.
- Week 4-8Peak benefit assessment.
- Week 8+Cycle decision point.
Side Effects & Safety
- Common (forum): Headache, mild jitter, irritability
- Less common: Insomnia if late-dosed, GI upset, anxiety
- Rare-serious: Seizure-threshold concerns are mechanism-driven (AMPA potentiation, by analogy with sunifiram and other ampakines) but no published case reports exist because no human use is documented in literature. The signal is weaker than for IDRA-21 (which is a clearly Type-II "high-impact" ampakine) — unifiram is more indirect — but mechanistically nonzero.
- Specific watch periods: N/A — no human safety dataset.
References
Galeotti et al. 2007 — Different involvement of type 1, 2, and 3 ryanodine receptors in memory processes (passive avoidance, sunifiram and unifiram in mice) (Pharmacol Biochem Behav)
Romero et al. 2002 — Sunifiram (DM-235) cognition enhancer characterization (Eur J Pharmacol)
Lynch 2006 — Glutamate-based therapeutic approaches: ampakines and racetams (review)
Martini et al. 2013 — Sunifiram NMDA glycine-site partial agonism (sister-compound mechanism reference)
How was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.